Allterum Therapeutics is a biopharmaceutical company focused on developing innovative immunotherapies for cancers expressing the IL-7 receptor (IL-7R). The company's primary product is a monoclonal antibody targeting CD127 (IL-7Rα), aimed at treating relapsed acute lymphoblastic leukemia and other IL-7R over-expressing cancers, including refractory solid tumors. Founded by Fannin Innovation Studio in Houston, TX, Allterum leverages cutting-edge research from the National Cancer Institute.
Allterum Therapeutics has made significant strides in oncology, particularly with its exclusive license of the 4A10 antibody from the National Cancer Institute. This antibody shows promise in targeting IL-7R expressing cancers, positioning Allterum as a leader in this niche market. The company's work has the potential to significantly impact cancer treatment, offering new hope for patients with difficult-to-treat malignancies.
